• Parkinson’s Symptoms Develop Slowly, Most Commonly After the Age of 50, and Include Tremor, Slowness in Movement, Limb Stiffness, Problems With Gait and Balance, Sleep Disorders, and Mental Health Issues.
  • People withinson’s Disease has to take a severe tablets Each Day to Help Allevate Their Symptoms.
  • Now, A Team of Scientists in Australia you have unveiled Weekly injection Treatment for Parkinson’s Disease.
  • If Further Research Proves The Injection’s Safety and Efficacy, The Long-Acting Implant could Be Life Changing for People Living With Parkinson’s.

Parkinson’s Disease is The Second Most Common Neurodegenerative Condition after Alzheimer’s Disease. IT AFFFECTS ALMOST 1.1 MILLION PEOPLE IN THE UNITED STATES AND MORE THAN 10 MILLION WORLDWIDE. Of these, 96% are diagnosed after the age of 50.

The Condition When Nerve Cells in an Area of The Brain Calleed The Substantia Nigra Stop producing angouh of the neurotransmitter dopamine. This leads to a Range of Symptomsincluding:

  • Tremor, or Shaking, In Hands, Arms, Legs, Jaw, Or Head
  • Muscle Stiffness
  • Slowness of Movement
  • Impaired Balance and Coordination.

The Two Main Treatments For Parkinson’s Disease Are Levodopa (L-Dopa), Which Nerve Cells Use to Make Dopamine, and Carbidopa, Which Increases The Efficacy of Levodopa and Helps Minimize ITS SIDE Effects. However, People Need to Take the Medications Several Times A Day, Which Many Find Difficult To Do.

NOW, Scientists in Australia have developed to Long-Action Injection Treatment Combining The Two Medications. The implant releases The Drugs Slowly Over Seven Days, People with the Condition Woold no Longer Have to take a multiple Tablets Event Day.

The Study Findings Suggest that the Injection Could Be “A promising system for the delivery of levodopa and carbidopa for parkinson’s patients.”

Sneha Mantri, MD MS, Chief Medical Officer for The Parkinson’s Foundation, Who Was Not Involved in the Study, AgreeD:

“If This Medication Is Safe and Effective in Humans, It Coul Be an alternative for People with (Parkinson’s) compared to multiple Daily Pills.”

The Findings are published in the journal Drug Delivery and Translational Research.

An alternative to multiple Daily Pills

The Injection Countins A Combination Of Levodopa (L-Dopa) and CarbidopaTwo Drugs used Together to Treat Parkinson’s Disease.

L-Dopa Can Cross The Blood-Brain Barrier Into the Central Nervous System, where it is converted to dopamine. People withinson’s Take L-Dopa to Control The Physical Symptoms Associated With The Lack of Dopamine Production.

Clinicians prescribes carbidopapapa in combination with l-dopa to increase ITS EFFICACY WITHIN THE NERVOUS SYSTEM, AND HELP Gastrointestinal Combat Symptoms, WHICH ARE A COMMON SIDE EFECT OF L-DOPA.

The Two Drugs are usually Taken in the Form of Capsules, Containing A Combination of the Drugs in Carefully Calculated Proportions. To reduce The Chance of Gastrointestinal Symptoms, They Should Be Taken With Meals. As fat and protein can decree The Absorption of L-Dopa, People Must Avoid High Fat Or High Protein Meals When Taking the Tablets.

How was The Injection Developed, and How Does It Work?

The Newly Developed Injection Also Administers A Combination of L-Dopa and Carbidopa in the form of an in-situ implant.

For Their Implant, The Refers Used Two Organic Polymers and A Solid, in different ratios to Achieve the Correct Rate of Drug Release. Eleven the correct ratio was determined, levodopa and carbidopa were added to create the implant.

They will performeted severely In-vitro Tests to determine The Effect of PH (ACID/Alkali Balance), How Easy It was to Inject the Implant, How Rapidly the Implant Degraed and the Drugs Were Disperse, and The Effect of the Implant On Cells.

They have tested the mechanism Ex vivo In Leg Muscle Tissue from A Pig.

The Implant Performed Similarly In vitro and Ex vivoRELEASING THE DRUGS SLOWLY OVER SIVERAL SEYS.

After Into Muscle Tissue, for Formed on the Surface of the Implant, Through the Drugs Diffused into the Tissue. UP to 90% of the Drug Was Relay Over 7 Days, and The Implant Broke Down Complety Within 2 Weeks.

The Formula That the Refers Develop Was Easy To Inject, So They Suggest That This Could Be A:

“Promising Drug Delivery System for Parkinson’s Patients, Which Will Reduces The Dosing Frequency in The Elderly Patients To Once-A-Week Injection.”

Potential Problems With Long-Action Injection

Jamie Adams, MD, Associate Professor of Neurology at The University of Rochester Medical Center, Who Was Not Involved in The Study, HighLight Potential Problems With The Treatment:

“Given Fluctuations in Parkinson’s Symptoms, It May Be Difficult To Determine APPROPRIATE dosing for an entire Week, and Patients May Still Require Oral Medications or Other Therapies. If the Weekly Injection is dosed too high, that COUL COUred Also Be problematic.”

And Mantri Also Raised submues like Will need to be addressed:

“Every medication is different, and This Type of Gel has not Been used for (Parkinson’s) Treatment Before. However, MANY INJECTABLE MEDICINES CARY THE RISK OF INJECTION Site Reactions (for Instance, Rash, Nodules) Related to The Delivery Method Iself.”

Promising Early Development Needs Further Testing

This is an early Stage of Development of a New Mechaanism of Drug Delivery for People Withinson’s Disease. But it has the potential to transform treatment for Elderly People withinson’s.

However, there are severe Further Stages of Testing That Would Need To Be Urtaker Before the Implant Could Be Licensed, As Mantri Told Medical News Today:

“This is a Vary Preliminary Study, looking at How the New Treatment Behaves in the Lab. Further Testing on Animals and The Humans Will Be Neudary As It Moverd Inward in Drug Development.”

“I Would Like to see the results of Animal Testing, as Well as Human Testing, to reure that This Is Bow Safe and Effective,” She Added.

ADAMS AGREED:

“This Treatment is Still Early, and There Needs to Be Human Studies, Including Randomized Controlled Trials, Evaluating Safety and Efficacy.”

“To Weekly Injection Therapy for Parkinson’s Disease Could reduces The Burden of Frequent Medication Dosing and May Improve Quality of Life.”

– Jamie Adams